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Dear Editor,
we read the article by Grein et al. [1] published in New 
England Journal of Medicine with interest. The new 
SARS-like coronavirus (now named SARS-CoV-2) that 
emerged in December 2019 has been shown to be clos-
est related (∼88%) to two bat-derived SARS-like CoVs 
(bat-SL-CoVZC45 and bat-SL-CoVZXC21), with ∼79% 
overall sequence identity to SARS-CoV and ∼50% to 
MERS-CoV [2]. Remdesivir is well known in antiviral 
treatment of coronaviruses (SARS, MERS) [3], hence 
its consideration for SARS-CoV-2 therapy. However, we 
must remember that the coronavirus induces the en-
dogenous expression of IFN-λ and/or blocks IFN-λ, af-
fecting inflammatory responses and mechanisms of tis-
sue damage and repair. The main function of IFN-λ is to 
prevent viral infection by establishing an antiviral state 
and, if infected, to slow down viral replication and dis-
semination. IFN-λ acted as a unique immunomodulato-
ry agent by modifying transcriptional and non-transla-
tional neutrophil responses, which might permit a con-
trolled development of the inflammatory process [4]. 
In vitro, treatment with IFN-λ showed potency against 
a variety of viruses, including SARS-CoV-1 and MERS-
CoV [5], and currently pegylated IFN-λ1 (peg-IFN-λ1) is 
the only IFN-λ currently available as a therapeutic agent.
In summary, to increase the therapeutic effect, it 
is therefore worth considering combined treatment 
of COVID-19 patients by using interferon lambda 
with Remdesivir.
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